Global pharmaceutical company Lupin Limited has entered into a licensing and supply agreement with Spektus Pharma to commercialize DeslaFlex in Canada, marking a strategic move to strengthen its central nervous system (CNS) portfolio in the region.
DeslaFlex is a novel antidepressant formulation designed for the management of Major Depressive Disorder (MDD). The therapy has been developed using Spektus’s proprietary Flexitab oral drug-delivery platform, which is intended to offer greater flexibility and improved patient-centric dosing options.
Under the agreement, Lupin will leverage its established commercial infrastructure and market presence in Canada to introduce DeslaFlex to healthcare providers and patients. The collaboration reflects a shared objective to expand access to differentiated treatment options in the field of mental health.
Claus Jepsen, President, Global Specialty at Lupin, noted that the agreement reinforces the company’s long-term strategy of expanding its CNS footprint while deepening its engagement with the Canadian healthcare ecosystem. He emphasized that adding DeslaFlex to Lupin’s portfolio aims to support clinicians in delivering more personalized and flexible treatment approaches for patients living with Major Depressive Disorder.
Zarvaan Merchant, Chief Executive Officer of Spektus Pharma, described the partnership as a significant milestone for the company as it advances from product development to commercial execution. He highlighted Lupin’s established brand and commercial strength in Canada as key factors in maximizing the product’s reach and impact.
The partnership also aligns with Canada’s supportive regulatory framework for innovative specialty therapies, positioning both companies to potentially build a broader platform for future launches in the CNS segment.
